InsiderTrades.com logo
Brandon S. Smith net worth and biography
  • Phone
  • Email
  • Website

Brandon Smith Biography and Net Worth

COO of Prothena

Brandon Smith has served as our Chief Operating Officer since September 2021. He served as Chief Business Officer from March 2020 through September 2021. Prior to joining Prothena in 2020, he was Chief Operating Officer at Iconic Therapeutics, Inc. (a biopharmaceutical company) from 2017 to 2020. From 2012 to 2017, Mr. Smith held senior positions at Impax Laboratories, LLC (a specialty pharmaceutical company), including Senior Vice President, and Vice President of Corporate Development and Strategy. Mr. Smith also held several positions of increasing responsibility at Amgen Inc. between 2005 and 2012, including Executive Director, Biosimilars Strategy, Director, Strategy and Corporate Development and Director, Operations Strategy. Mr. Smith was also a Consultant and Project Leader at The Boston Consulting Group between 2002 and 2005. Mr. Smith earned his B.S. in Chemical Engineering at the University of Michigan and his M.B.A. from The University of Texas at Austin McCombs Graduate School of Business.

How old is Brandon S. Smith?

Mr. Smith is currently 49 years old. There are 6 older executives and no younger executives at Prothena. The oldest executive at Prothena is Ms. Carol D. Karp, Chief Regulatory Officer, who is 71 years old. Learn More on Brandon S. Smith's age.

How do I contact Brandon S. Smith?

The corporate mailing address for Mr. Smith and other Prothena executives is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. Prothena can also be reached via phone at (531) 236-2500 and via email at [email protected]. Learn More on Brandon S. Smith's contact information.

Has Brandon S. Smith been buying or selling shares of Prothena?

Brandon S. Smith has not been actively trading shares of Prothena within the last three months. Learn More on Brandon S. Smith's trading history.

Who are Prothena's active insiders?

Prothena's insider roster includes Christopher Henney (Director), Carol Karp (Insider), Gene Kinney (Pres), Michael Malecek (Insider), Tran Nguyen (CFO & Chief Strategy Officer ), Dennis Selkoe (Director), Brandon Smith (COO), Karin Walker (CAO), and Wagner Zago (Insider). Learn More on Prothena's active insiders.

Are insiders buying or selling shares of Prothena?

During the last twelve months, Prothena insiders bought shares 4 times. They purchased a total of 207,436 shares worth more than $2,750,103.48. The most recent insider tranaction occured on January, 14th when Major Shareholder William P Scully bought 100,000 shares worth more than $1,279,000.00. Insiders at Prothena own 10.0% of the company. Learn More about insider trades at Prothena.

Information on this page was last updated on 1/14/2025.

Brandon S. Smith Insider Trading History at Prothena

See Full Table

Brandon S. Smith Buying and Selling Activity at Prothena

This chart shows Brandon S. Smith's buying and selling at Prothena by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Prothena Company Overview

Prothena logo
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.
Read More

Today's Range

Now: $11.16
Low: $10.95
High: $11.57

50 Day Range

MA: $10.27
Low: $9.41
High: $11.17

2 Week Range

Now: $11.16
Low: $4.32
High: $17.66

Volume

1,161,191 shs

Average Volume

569,200 shs

Market Capitalization

$600.74 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A